CAMBRIDGE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) will webcast its presentations at the 2006 Merrill
Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on
February 8, 2006 and at the Eighth Annual BIO CEO and Investor Conference on
February 14, 2006.
Joshua Boger, Ph.D., Chairman, President and Chief Executive Officer of
Vertex will present at both conferences. Vertex's presentation and discussion
at the Merrill Lynch conference will be conducted on February 8, 2006 at 8:40
a.m. EST and will be audio webcast only. At the BIO CEO and Investor
Conference, Dr. Boger will deliver a corporate presentation on Tuesday,
February 14, 2006 at 12:00 p.m. EST. In addition, Dr. Boger will participate
in the Infectious Disease: Breakthroughs in Hepatitis Focus Session at 9:00
a.m. EST on that day. This Focus Session will also be webcast.
The presentations will be webcast live and may be accessed by visiting the
Vertex website at http://www.vrtx.com. A replay of the webcasts will also be
available on the Company's website for two weeks following the presentations.
To access the webcasts, go to Vertex's website and select the 'Merrill Lynch
Global Pharmaceutical, Biotechnology & Medical Device Conference' or the 'BIO
CEO and Investor Conference' or the 'BIO CEO Breakthroughs in Hepatitis Focus
Session' from the 'Events Calendar.' To ensure a timely connection, it is
recommended that users register at least 15 minutes prior to the scheduled
webcast.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is principally focused on viral
diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes
the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at http://www.vrtx.com.
Vertex Contact:
Lora Pike, Manager, Investor Relations, (617) 444-6755
SOURCE Vertex Pharmaceuticals Incorporated
 back to top
Related links:
http://www.vrtx.com
Company News On-Call:
http://www.prnewswire.com/comp/938395.html
CONTACT:
Lora Pike, Manager, Investor Relations of
Vertex, +1-617-444-6755
|
